Abstract:Most of patients harboring EGFR activating mutations will inevitably acquire resistance to EGFR-TKI after 6-12 months of treatment. The T790M mutation in exon 20 of EGFR gene is the main cause of drug resistance, accounting for about 50%. The third-generation TKI targeting T790M mutation has been marketed and used in clinical practice, such as Osimertinib (AZD9291), but there are still nearly 50% of TKI resistance mechanisms unknown or currently lack of clinical approaches for reversing drug resistance. Therefore, exploring the molecular mechanism of T790M-negative EGFR-TKI secondary drug resistance has become a hot spot in lung cancer research. A growing number of studies found that microRNA (miRNA) plays an important role in the regulation of acquired drug resistance of EGFR-TKI, and it is expected to reverse acquired resistance of EGFR TKIs. Cell viabilities of PC9 and PC9/BB4 cells was detected by CCK-8 method, the EdU method was used to detect cell proliferation, cell apoptosis was detected by FACS, and plate colony assay was used to detect colony formation ability. Western blot detected to difference of EGFR downstream signaling pathways in PC9 and PC9/BB4 cells. The results of in vitro experiments indicated that miR-338-3p was down-regulated in Gefitinib-sensitive PC9 cell and highly expressed in PC9/BB4 resistant cells. Up-regulation or down-regulation of miR-338-3p, respectively, can alter the effect of Gefitinib on the survival, proliferation, apoptosis and clonality of PC9 and PC9/BB4 cells, and can regulate the activity of p-Akt and p-Erk1/2 protein, indicating miR -338-3p promotes EGFR-TKI resistance in non-small cell lung cancer by activating EGFR downstream signaling pathway. Using bioinformatics software to predict and confirm by dual luciferase reporter system, PTPN12 is a downstream target gene of miR-338-3p. PTPN12 protein is highly expressed in PC9 cells, low in PC9/BB4 cells, and can interfere with Gefitinib sensitivity after interfering with PTPN12 expression level in PC9 and PC9/BB4 cells, respectively. In vitro experiments demonstrated that miR-338-3p activates EGFR downstream PI3K/Akt and Ras/Raf/Erk signaling pathways by targeting PTPN12, and promote Gefitinib resistance in non-small cell lung cancer. Further study showed that down-regulation of miR-338-3p by miR-338-3p antagomir reversed the resistance of PC9/BB4 xenografts to Gefitinib by activating PTPN12. We conclude that alteration of miR-338-3p/PTPN12 expression as a novel mechanism for EGFR-TKI resistance in NSCLC. miR-338-3p/PTPN12 could serve as a therapeutic target for overcoming EGFR-TKI resistance in NSCLC.

The Role of miR-29a and miR-143 on the Anti-apoptotic MCL-1/cIAP-2 Genes Expression in EGFR Mutated Non-small Cell Lung Carcinoma Patients

MiRNA-195-5p Functions As a Tumor Suppressor and a Predictive of Poor Prognosis in Non-small Cell Lung Cancer by Directly Targeting CIAPIN1

MiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell Lines

Mir‑654‑3p Suppresses Cell Viability and Promotes Apoptosis by Targeting RASAL2 in Non‑small‑cell Lung Cancer.

Identification of Plasma Microrna Profiles for Primary Resistance to EGFR-TKIs in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Activating Mutation.

miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer

microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation

The novel miR-873-5p-YWHAE-PI3K/AKT axis is involved in non-small cell lung cancer progression and chemoresistance by mediating autophagy

MicroRNA-29 Targets FGF2 and Inhibits the Proliferation, Migration and Invasion of Nasopharyngeal Carcinoma Cells Via PI3K/AKT Signaling Pathway

MicroRNAs Reduce Tumor Growth and Contribute to Enhance Cytotoxicity Induced by Gefitinib in Non-Small Cell Lung Cancer

Plasma Microrna Signatures to Predict Egfr-Tki Resistance in Egfr-Mutant Advanced Nsclc Patients.

MicroRNA-15a Induces Cell Apoptosis and Inhibits Metastasis by Targeting BCL2L2 in Non-Small Cell Lung Cancer

P077 Mir-338-3p Promotes the Resistance of Non-Small Cell Lung Cancers to EGFR-TKI by Targeting PTPN12

EGFR-AS1 Promotes Nonsmall Cell Lung Cancer (NSCLC) Progression via Downregulating the miR-524-5p/DRAM1 Axis and Inhibiting Autophagic Lysosomal Degradation

The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in EGFR-Mutant NSCLC

Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer

Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance in EGFR-mutant NSCLC by targeting integrin beta3

MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines

Epidermal Growth Factor Receptor Expression Affects Proliferation and Apoptosis in Non-Small Cell Lung Cancer Cells Via the Extracellular Signal-Regulated Kinase/microrna 200a Signaling Pathway.

Mir-146a Inhibits Cell Growth, Cell Migration and Induces Apoptosis in Non-Small Cell Lung Cancer Cells

Cell Behavior of Non-Small Cell Lung Cancer Is at EGFR and MicroRNAs Hands